# InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Signs Agreement to Advance MS Drug Toward Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) has signed an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for its lead compound, Lucid-21-302 (Lucid-MS), targeting multiple sclerosis. The IND submission to the FDA is planned for the fourth quarter of 2025 and, if accepted, would enable the company to initiate a Phase 2 clinical trial. Lucid-21-302 is a patented, non-immunomodulatory neuroprotective therapy shown in preclinical studies to prevent demyelination, a key driver of MS and other neurodegenerative disorders.

 To view the full press release, visit https://ibn.fm/E5Lau

 About Quantum BioPharma Ltd.

 Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD and spun out its OTC version to a company, Celly Nutrition Corp. (“ Celly Nutrition ”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

 NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-quantum-biopharma-ltd-nasdaq-qntm-signs-agreement-to-advance-ms-drug-toward-phase-2-trial/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/quantum-biopharma-signs-agreement-for-lucid-ms-ind-application/df196600ea15003c7af1f40d715d8ec6) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1kr5l9p/quantum_biopharma_signs_agreement_for_lucidms_ind/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/20/pitapico1WAD.webp)